MIRM
Mirum Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +18.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.39K | $161,236 | n/a | n/a |
| Q2 2026 | 105 | +1 | 35.65M | $4.17B | +8 | −7 |
| Q1 2026 | 107 | +6 | 39.52M | $3.63B | +12 | −7 |
| Q4 2025 | 102 | +1 | 36.05M | $2.83B | +2 | n/a |
| Q3 2025 | 20 | 0 | 17.64M | $1.29B | n/a | n/a |
| Q2 2025 | 17 | +1 | 13.61M | $692.65M | +2 | −1 |
| Q1 2025 | 13 | +1 | 7.45M | $335.67M | +2 | −1 |
| Q4 2024 | 12 | 0 | 6.63M | $274.04M | +1 | −1 |
| Q3 2024 | 11 | +2 | 4.84M | $188.84M | +2 | n/a |
| Q2 2024 | 9 | n/a | 4.39M | $149.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.60M | +0.7% | $264.09M | 0.0% | ▲ Add | 2 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (passive) | 2.55M | -0.8% | $186.60M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 1.35M | -2.1% | $98.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.28M | -9.4% | $94.08M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 1.04M | -26.0% | $76.28M | 0.1% | ▼ Trim | 6 | SEC ↗ ×3 |
| 6 | Geode Capital Management ✦ (passive) | 1.01M | -1.9% | $74.06M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 923.51K | +66.4% | $67.70M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 790.69K | +566.9% | $57.97M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 9 | Point72 Asset Management ✦ | 790.67K | +205.4% | $57.96M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 670.15K | n/a | $49.13M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 11 | Fidelity (FMR) ✦ | 640.22K | +977.1% | $46.93M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 12 | Arrowstreet Capital ✦ | 612.32K | +709.5% | $44.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 513.45K | +29.5% | $37.64M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 497.47K | +104.7% | $36.47M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 15 | Goldman Sachs Group ✦ | 450.84K | n/a | $33.05M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 343.13K | +99.7% | $25.15M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Millennium Management ✦ | 309.03K | +7.2% | $22.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | JPMorgan Chase ✦ | 200.42K | n/a | $14.69M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 19 | Marshall Wace ✦ | 39.83K | +56.0% | $2.92M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 31.39K | -33.9% | $2.30M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 308 holders, 67.83M shares, $6.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.94K sh · $978,093
Officer · 658 sh · $65,800
Officer · 40.00K sh · $4.00M
Officer · 6.00K sh · $599,510
Officer, Director · 2.30K sh · $230,322
Officer, Director · 6.02K sh · $597,187
Officer, Director · 11.68K sh · $1.15M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology